Shapiro M, Green C, Faybush E M, Esquivel R F, Fass R
The Neuro-Enteric Clinical Research Group, Section of Gastroenterology, Department of Medicine, Southern Arizona VA Health Care System and University of Arizona Health Sciences Center, Tucson, AZ 85723-0001, USA.
Aliment Pharmacol Ther. 2006 Jan 15;23(2):321-9. doi: 10.1111/j.1365-2036.2006.02747.x.
BACKGROUND: Studies have demonstrated that patients with Barrett's oesophagus have the highest oesophageal acid exposure profile, followed by erosive oesophagitis and non-erosive reflux disease patients, but the exact extent of overlap remains unknown. AIM: To determine the extent of overlap in oesophageal acid exposure among the different gastro-oesophageal reflux disease groups. METHODS: A total of 121 patients with gastro-oesophageal reflux disease underwent an upper endoscopy and were classified as having Barrett's oesophagus, erosive oesophagitis and non-erosive reflux disease-all (non-erosive reflux disease-positive and functional heartburn). Subsequently, patients underwent pH testing and overlap in oesophageal acid exposure among the different gastro-oesophageal reflux disease groups was determined. RESULTS: Of those enrolled, 24 had Barrett's oesophagus, 30 erosive oesophagitis and 28 were non-erosive reflux disease-positive. Mean oesophageal acid exposure time was 224.8 +/- 35, 134.3 +/- 21.9 and 141.3 +/- 19.8 min for Barrett's oesophagus, erosive oesophagitis and non-erosive reflux disease-positive respectively. Per cent overlap for total, upright and supine time between non-erosive reflux disease-positive and erosive oesophagitis was 47.4%, 64.7% and 81.8%, between Barrett's oesophagus and erosive oesophagitis was 47.8%, 40.7% and 24%, and between Barrett's oesophagus and non-erosive reflux disease-positive was 31.6%, 37.5% and 20.8% respectively. CONCLUSIONS: Our study demonstrated a high oesophageal acid exposure overlap between patients with non-erosive reflux disease-positive and erosive oesophagitis, Barrett's oesophagus and erosive oesophagitis, as well as Barrett's oesophagus and non-erosive reflux disease-positive patients.
Aliment Pharmacol Ther. 2006-1-15
Aliment Pharmacol Ther. 2007-1-1
Aliment Pharmacol Ther. 2003-2-15
Rev Esp Enferm Dig. 1990-3
Neurogastroenterol Motil. 2009-8
Transl Gastroenterol Hepatol. 2025-7-23
Ann Gastroenterol. 2013
Gastroenterol Res Pract. 2013-7-11
BMC Gastroenterol. 2013-5-11
Nat Rev Gastroenterol Hepatol. 2013-3-26
World J Gastroenterol. 2012-5-21